EURODIA - Functional genomics of pancreatic beta cells and of tissues involved in control of the endocrine pancreas for prevention and treatment of type 2 diabetes (FP6-LIFESCIHEALTH) (2006-03-01 - 2010-02-28) (»add to infobox)

Sigurd LENZEN, Frances Mary ASHCROFT, Naama BARKAI, Per-Olof BERGGREN, Helena EDLUND, Decio L. EIZIRIK, Jorge FERRER, Philippe FROGUEL, Andrew HATTERSLEY, Cecilia HOLM, C. Victor JONGENEEL, Piero MARCHETTI, Jorgina SATRÚSTEGUI, Frans C. SCHUIT, Bernard THORENS, Claes B. WOLLHEIM, Alexander KEL, Kader THIAM, Pascale NONY

MEDIZINISCHE HOCHSCHULE HANNOVER (DE929 - Region Hannover) (Germany), THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (UKJ14 - Oxfordshire) (Great Britain), WEIZMANN INSTITUTE OF SCIENCE (NoRegion - NoRegion) (Israel), KAROLINSKA INSTITUTET (SE010 - Stockholms län) (Sweden), UMEA UNIVERSITET (SE081 - Västerbottens län) (Sweden), UNIVERSITE LIBRE DE BRUXELLES (BE100 - Arr. de Bruxelles-Capitale) (Belgium), INSTITUT D'INVESTIGACIONS BIOMEDIQUES AUGUST PI-SUNYER (ES511 - Barcelona) (Spain), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR101 - Paris) (France), THE UNIVERSITY OF EXETER (UKK43 - Devon CC) (Great Britain), LUNDS UNIVERSITET (SE044 - Skåne län) (Sweden), INSTITUT SUISSE DE BIOINFORMATIQUE (CH012 - Valais) (Switzerland), UNIVERSITA DI PISA (ITE17 - Pisa) (Italy), UNIVERSIDAD AUTONOMA DE MADRID (ES300 - Madrid) (Spain), KATHOLIEKE UNIVERSITEIT LEUVEN (BE242 - Arr. Leuven) (Belgium), UNIVERSITE DE LAUSANNE (CH022 - Freiburg) (Switzerland), UNIVERSITE DE GENEVE (CH012 - Valais) (Switzerland), BIOBASE GMBH (DE91B - Wolfenbüttel) (Germany), GENOWAY SA (FR716 - Rhône) (France), TRANSAT SA (FR716 - Rhône) (France)

Failure of pancreatic beta cells to maintain adequate functional capacity leads to increasing blood glucose levels and subsequent type 2 diabetes (T2DM). This disease imposes a huge, and growing, socio-economic burden on European and global societies. However, the pathophysiological mechanisms underlying beta cell dysfunction remain poorly understood, limiting the availability of novel approaches to treat or prevent T2DM. Here, we propose an Integrated Project that will lead to an unprecedented understanding of the factors influencing the maintenance (and loss) of normal beta cell functional capacity. This will be realized through the application of functional genomics technologies in an integrated and systematic approach, which employs studies in cellular and animal models as well as genetic analysis of human monogenie and polygenic T2DM patients. The project will integrate leading European experts in islet diabetes research, human geneticists, bioinformaticians and computational scientists as well as SMEs. Specific aims will be to: - Dissect the molecular pathways and identify key regulatory events - including those contributed by tissues located outside the endocrine pancreas - that control the ability of the beta cell to maintain its secretory function over a lifetime. - Identify key pathophysiological events in the above pathways that become dysfunctional in T2DM and determine the contributions of lipotoxicity, glucotoxicity, oxidative stress and me impact of genetic variations in the induced beta cell dysfunction. - Select genes and proteins that are candidates in the pathogenesis of beta cell dysfunction and assess their physiological role and potential value as novel drug targets for prevention and treatment of T2D. Collectively this program will lead to an unprecedented understanding of beta cell molecular physiology and pathophysiology to pave the way for improved health in Europe.

PERSONS (19/19)

RELATED NAVIGATION AREA(S) (1/1)